Celldex Therapeutics said it will stop investigating its mast cell-targeting monoclonal antibody in prurigo nodularis after its Phase 2 study missed all efficacy measures. The setback sends a clear signal that the mechanism may not deliver in that chronic itch population, even as the company continues exploring barzolvolimab in other indications.